Skip to content
2000
Volume 6, Issue 3
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

Background

Melatonin has proven antioxidant and anti-inflammatory properties that may address the pathophysiology of coronavirus disease 2019 (COVID-19). Therefore, the current study was conducted to evaluate the safety and efficacy of melatonin in COVID-19.

Methods

In this single-center, randomized, double-blind, placebo-controlled clinical trial, 96 adults hospitalized with mild to moderate COVID-19 were recruited. The participants were allocated into the melatonin and the placebo groups, randomly (1:1 ratio).

Results

The primary outcomes were a reduction in the length of hospital stay, the rate of ICU admissions, intubation/mechanical ventilation, and mortalities within 14 days of starting the treatment compared to the placebo group. After two weeks of follow-up, the blood oxygen saturation and the respiratory rate significantly improved in the melatonin group. C-reactive protein, erythrocyte sedimentation rate, lactate dehydrogenase, creatine phosphokinase, Ferritin, and D-dimer levels were significantly decreased in the melatonin group. Conversely, these markers were considerably increased in the placebo group. These serum marker levels also showed a significant difference in between-group comparison. The comparison of clinical endpoints between the two groups showed no significant difference.

Conclusion

This clinical trial study indicated that the combination of oral melatonin tablets and standard treatment could substantially improve blood oxygen saturation and inflammatory factors in mild to moderate hospitalized COVID-19 patients.

Clinical Trial Registration

Clinical Trials (IRCT registration number: IRCT20200408046988N1).

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975282054240328072229
2024-04-05
2025-09-27

  • From This Site

    /content/journals/covid/10.2174/0126667975282054240328072229
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Davoudi-MonfaredE. RahmaniH. KhaliliH. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19.Antimicrob. Agents Chemother.2020649e01061e2010.1128/AAC.01061‑20 32661006
     [Google Scholar]
  2. GrasselliG. ZangrilloA. ZanellaA. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy.JAMA2020323161574158110.1001/jama.2020.5394 32250385
     [Google Scholar]
  3. MehtaP. McAuleyD.F. BrownM. SanchezE. TattersallR.S. MansonJ.J. COVID-19: Consider cytokine storm syndromes and immunosuppression.Lancet2020395102291033103410.1016/S0140‑6736(20)30628‑0 32192578
     [Google Scholar]
  4. WuC. ChenX. CaiY. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.JAMA Intern. Med.2020180793494310.1001/jamainternmed.2020.0994 32167524
     [Google Scholar]
  5. PoursadeghF. DavoudianN. MozdourianM. AbdollahiF. Synchronous presentation of COVID-19 pneumonia and pulmonary embolism.Clin. Case Rep.2021931663166610.1002/ccr3.3870
     [Google Scholar]
  6. ScottonC.J. ChambersR.C. Molecular targets in pulmonary fibrosis: The myofibroblast in focus.Chest200713241311132110.1378/chest.06‑2568 17934117
     [Google Scholar]
  7. CrossK.M. LandisD.M. SehgalL. PayneJ.D. Melatonin for the early treatment of COVID-19: A narrative review of current evidence and possible efficacy.Endocr. Pract.202127885085510.1016/j.eprac.2021.06.001 34119679
     [Google Scholar]
  8. BortolottiD. GentiliV. RizzoS. TLR3 and TLR7 RNA sensor activation during SARS-CoV-2 infection.Microorganisms202199182010.3390/microorganisms9091820 34576716
     [Google Scholar]
  9. ShchetininE. BaturinV. ArushanyanE. BolatchievA. BobryshevD. Potential and Possible Therapeutic Effects of Melatonin on SARS-CoV-2 Infection.Antioxidants202211114010.3390/antiox11010140 35052644
     [Google Scholar]
  10. TanD.X. HardelandR. Estimated doses of melatonin for treating deadly virus infections: Focus on COVID-19.Melaton Res20203327629610.32794/mr11250062
     [Google Scholar]
  11. Acuña-CastroviejoD. EscamesG. FigueiraJ.C. de la OlivaP. BorobiaA.M. FernándezA.C. Clinical trial to test the efficacy of melatonin in COVID‐19.J. Pineal Res.2020693e1268310.1111/jpi.12683 32770854
     [Google Scholar]
  12. JuybariB.K. PourhanifehM.H. HosseinzadehA. HematiK. MehrzadiS. Melatonin potentials against viral infections including COVID-19: Current evidence and new findings.Virus Res.202028719810810.1016/j.virusres.2020.198108 32768490
     [Google Scholar]
  13. FatemehG. SajjadM. NiloufarR. NedaS. LeilaS. KhadijehM. Effect of melatonin supplementation on sleep quality: A systematic review and meta-analysis of randomized controlled trials.J. Neurol.2022269120521610.1007/s00415‑020‑10381‑w 33417003
     [Google Scholar]
  14. PierceM. LinneburS.A. PearsonS.M. FixenD.R. Optimal melatonin dose in older adults: A clinical review of the literature.Sr. Care Pharm.201934741943110.4140/TCP.n.2019.419 31383052
     [Google Scholar]
  15. SwansonK.V. DengM. TingJ.P.Y. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics.Nat. Rev. Immunol.201919847748910.1038/s41577‑019‑0165‑0 31036962
     [Google Scholar]
  16. ReiterR.J. MaQ. SharmaR. Melatonin in mitochondria: Mitigating clear and present dangers.Physiology2020352869510.1152/physiol.00034.2019 32024428
     [Google Scholar]
  17. FeitosaE.L. JúniorF.T.D.S.S. Nery NetoJ.A.D.O. COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor.Int. J. Med. Sci.202017142133214610.7150/ijms.48053 32922174
     [Google Scholar]
  18. SrinivasanV. MohamedM. KatoH. Melatonin in bacterial and viral infections with focus on sepsis: A review.Recent Pat. Endocr. Metab. Immune Drug Discov.201261303910.2174/187221412799015317 22264213
     [Google Scholar]
  19. MarsegliaL. ReiterR. BuonocoreG. GittoE. D’AngeloG. Melatonin and neonatal sepsis: A promising antioxidant adjuvant agent.Am. J. Perinatol.201734141382138810.1055/s‑0037‑1604244 28704851
     [Google Scholar]
  20. HendersonR. KimS. LeeE. Use of melatonin as adjunctive therapy in neonatal sepsis: A systematic review and meta-analysis.Complement. Ther. Med.20183913113610.1016/j.ctim.2018.06.002 30012383
     [Google Scholar]
  21. CarballoM.A. LópezP.R. CaleroJ.A. Protective effect of melatonin administration against SARS-CoV-2 infection: A systematic review.Curr. Issues Mol. Biol.2021441314510.3390/cimb44010003 35723382
     [Google Scholar]
  22. SrinivasanV. PerumalP.S.R. SpenceD.W. KatoH. CardinaliD.P. Melatonin in septic shock: Some recent concepts.J. Crit. Care2010254656.e1656.e6
     [Google Scholar]
  23. ReynoldsF.D. DauchyR. BlaskD. DietzP.A. LynchD. ZuckermanR. The pineal gland hormone melatonin improves survival in a rat model of sepsis/shock induced by zymosan A.Surgery2003134347447910.1067/S0039‑6060(03)00253‑8 14555936
     [Google Scholar]
  24. SchulzK.F. AltmanD.G. MoherD. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials.J. Pharmacol. Pharmacother.20101210010710.4103/0976‑500X.72352 21350618
     [Google Scholar]
  25. RovinB.H. AdlerS.G. BarrattJ. KDIGO 2021 clinical practice guideline for the management of glomerular diseases.Kidney Int.20211004S1S27610.1016/j.kint.2021.05.021 34556256
     [Google Scholar]
  26. HoP.M. BrysonC.L. RumsfeldJ.S. Medication adherence.Circulation2009119233028303510.1161/CIRCULATIONAHA.108.768986 19528344
     [Google Scholar]
  27. WhiteheadA.L. JuliousS.A. CooperC.L. CampbellM.J. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable.Stat. Methods Med. Res.20162531057107310.1177/0962280215588241 26092476
     [Google Scholar]
  28. CamposL.A. Cipolla-NetoJ. AmaralF.G. MicheliniL.C. BaderM. BaltatuO.C. The angiotensin-melatonin axis.Int. J. Hypertens.201320131710.1155/2013/521783 23365722
     [Google Scholar]
  29. NiW. YangX. YangD. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19.Crit. Care202024142210.1186/s13054‑020‑03120‑0 32660650
     [Google Scholar]
  30. DaviesD.A. AdlimoghaddamA. AlbensiB.C. The effect of COVID-19 on NF-κB and neurological manifestations of disease.Mol. Neurobiol.20215884178418710.1007/s12035‑021‑02438‑2 34075562
     [Google Scholar]
  31. SallesC. Correspondence COVID-19: Melatonin as a potential adjuvant treatment.Life Sci.202025311771610.1016/j.lfs.2020.117716 32334009
     [Google Scholar]
  32. XiaY. ChenS. ZengS. Melatonin in macrophage biology: Current understanding and future perspectives.J. Pineal Res.2019662e1254710.1111/jpi.12547 30597604
     [Google Scholar]
  33. MousaviS.A. HeydariK. MehravaranH. Melatonin effects on sleep quality and outcomes of COVID‐19 patients: An open‐label, randomized, controlled trial.J. Med. Virol.202294126327110.1002/jmv.27312 34460132
     [Google Scholar]
  34. HlutkinS. ZinchukV. Effect of melatonin on the blood oxygen transport during hypothermia and rewarming in rats.Adv. Med. Sci.200853223423910.2478/v10039‑008‑0035‑7 18930873
     [Google Scholar]
  35. ZinchukV.V. PoluyanI.A. HlutkinS.V. Effects of melatonin on the oxygen transport in blood, gas transmitters, and prooxidant–Antioxidant balance in the exercise.Hum. Physiol.201945669370010.1134/S0362119719050219
     [Google Scholar]
  36. ZarezadehM. KhorshidiM. EmamiM. Melatonin supplementation and pro-inflammatory mediators: A systematic review and meta-analysis of clinical trials.Eur. J. Nutr.20205951803181310.1007/s00394‑019‑02123‑0 31679041
     [Google Scholar]
  37. FarnooshG. AkbariqomiM. BadriT. Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID-19: A randomized, double-blind clinical trial.Arch. Med. Res.2022531798510.1016/j.arcmed.2021.06.006 34229896
     [Google Scholar]
  38. HasanZ.T. Al-AtrakjiM.Q.Y.M.A. AlsaatyM.H. AbdulnafaZ.D. MehuaidenA.K. The effect of melatonin on C-reactive protein, serum ferritin and D-dimer in COVID-19 patients.Int J Drug Deliv Technol202212110811210.25258/ijddt.12.1.21
     [Google Scholar]
  39. AlizadehN. DianatkhahM. AlimohamadiY. High dose melatonin as an adjuvant therapy in intubated patients with COVID-19: A randomized clinical trial.J. Taibah Univ. Med. Sci.202217345446010.1016/j.jtumed.2022.04.012 35581997
     [Google Scholar]
  40. HasanZ.T. AtrakjiD.M.Q.Y.M.A.A. MehuaidenD.A.K. The effect of melatonin on thrombosis, sepsis and mortality rate in COVID-19 patients.Int. J. Infect. Dis.2022114798410.1016/j.ijid.2021.10.012 34653660
     [Google Scholar]
  41. FaridzadehA. TabashiriA. MiriH.H. MahmoudiM. The role of melatonin as an adjuvant in the treatment of COVID-19: A systematic review.Heliyon2022810e1090610.1016/j.heliyon.2022.e10906 36254292
     [Google Scholar]
  42. WangX.C. WuG.L. CaiY.F. ZhangS.J. The safety and efficacy of melatonin in the treatment of COVID-19: A systematic review and meta-analysis.Medicine202210139e3087410.1097/MD.0000000000030874 36181086
     [Google Scholar]
  43. LanS.H. LeeH.Z. ChaoC.M. ChangS.P. LuL.C. LaiC.C. Efficacy of melatonin in the treatment of patients with COVID‐19: A systematic review and meta‐analysis of randomized controlled trials.J. Med. Virol.20229452102210710.1002/jmv.27595 35032042
     [Google Scholar]
  44. HuangP.Y. WuJ.Y. LiuT.H. The clinical efficacy of melatonin in the treatment of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.Front. Med.202310117129410.3389/fmed.2023.1171294 37181363
     [Google Scholar]
  45. AmeriA. Frouz AsadiM. ZiaeiA. Efficacy and safety of oral melatonin in patients with severe COVID-19: A randomized controlled trial.Inflammopharmacology202331126527410.1007/s10787‑022‑01096‑7 36401728
     [Google Scholar]
  46. Sánchez-RicoM. de la MuelaP. Herrera-MoruecoJ.J. GeoffroyP.A. LimosinF. HoertelN. Melatonin does not reduce mortality in adult hospitalized patients with COVID-19: A multicenter retrospective observational study.J. Travel Med.2022293taab19510.1093/jtm/taab195 35137210
     [Google Scholar]
  47. RazkenariK.E. BehdaniN.F. SalahshoorA. HeydariF. AlipourA. BaradariA.G. Melatonin as adjunctive therapy in patients admitted to the COVID-19.Ann. Med. Surg.20227610349210.1016/j.amsu.2022.103492 35287296
     [Google Scholar]
/content/journals/covid/10.2174/0126667975282054240328072229
Loading
Efficacy of Melatonin as an Adjunctive Therapy in Hospitalized Patients with Mild to Moderate COVID-19: A Randomized, Double-blind Clinical Trial
Coronaviruses 6, E050424228709 (2025); https://doi.org/10.2174/0126667975282054240328072229
/content/journals/covid/10.2174/0126667975282054240328072229
/content/journals/covid/10.2174/0126667975282054240328072229
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): acute-phase proteins; adjunctive therapy; antioxidants; COVID-19; Melatonin; SARS-CoV-2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test